Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery

Completed

Conditions studied: Erythropoietin, Acute Kidney Injury, Renal Biomarker

In brief

The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between Erythropoietin (EPO) levels and acute kidney injury after cardiac surgery. An early biomarker for kidney injury may be helpful in identifying, monitoring and managing patients at risk for kidney failure after cardiac surgery. To evaluate Erythropoietin's role as a predictor of poor renal function in the immediate post-bypass period we plan to compare EPO levels to Neutrophil gelatinase-associated lipocalin (NGAL).

Key facts

Study ID

NCT01393418

Run by

University of Michigan

People needed

80

Starts

2010-11-01

Expected to finish

2012-03-01

Last updated by the study team

2016-12-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cardiac surgery with cardiopulmonary bypass with DHCA
• Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL
• Adult male and female patients 18 years and older

You may not qualify if…

• VADS
• Emergent cases
• Prolonged hypoxemia before, during or after bypass
• End stage renal disease
• Patients receive erythropoietin receptor agonists

Where it is running

• University of Michigan Hospital — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.